Akoya Biosciences (AKYA) Reports Q3 Loss, Lags Revenue Estimates

Company Performance - Akoya Biosciences reported a quarterly loss of $0.18 per share, which was better than the Zacks Consensus Estimate of a loss of $0.19, and an improvement from a loss of $0.26 per share a year ago, indicating an earnings surprise of 5.26% [1] - The company posted revenues of $18.81 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 25.39%, and down from $25.22 million in the same quarter last year [2] - Over the last four quarters, Akoya has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Stock Performance - Akoya shares have declined approximately 34.2% since the beginning of the year, contrasting with the S&P 500's gain of 25.5% [3] - The current Zacks Rank for Akoya is 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $31.59 million, and for the current fiscal year, it is -$0.99 on revenues of $98.35 million [7] - The outlook for the Medical - Biomedical and Genetics industry, where Akoya operates, is currently in the top 29% of over 250 Zacks industries, indicating a favorable environment for potential stock performance [8]